Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV–1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)

التفاصيل البيبلوغرافية
العنوان: Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV–1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)
المؤلفون: Daniel Podzamczer, Sandra Morenilla, Brian Van Horne, Sofía Scévola, Amanda P. Schauer, Victor Urrea, Pere Domingo, Javier Martinez-Picado, Ana C Silva-Klug, Angela D. M. Kashuba, Eugenia Negredo, Mackenzie L. Cottrell, Benito Garcia, Jordi Niubó, Juan Tiraboschi, Arkaitz Imaz, Ivan Chivite
المصدر: Clin Infect Dis
بيانات النشر: Oxford University Press (OUP), 2020.
سنة النشر: 2020
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Microbiology (medical), Anti-HIV Agents, Pyridones, 030106 microbiology, HIV Infections, Emtricitabine, Tenofovir alafenamide, Piperazines, Andrology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Blood plasma, Humans, Medicine, Genitalia, Prospective Studies, 030212 general & internal medicine, Tenofovir, Online Only Articles, Alanine, Bictegravir, business.industry, HIV/AIDS research, Rectum, RNA, Amides, Infectious Diseases, HIV-1, Population study, Female, business, Heterocyclic Compounds, 3-Ring, medicine.drug
الوصف: BackgroundThe pharmacokinetics of bictegravir (BIC) and its association with the decay of human immunodeficiency virus (HIV)–1 RNA in genital fluids and the rectum have not yet been addressed.MethodsWe conducted a prospective, multicenter study of antiretroviral-naive people living with HIV-1 and initiating BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF). HIV-1 RNA was measured (limit of quantification, 40 copies/mL) in blood plasma (BP), seminal plasma (SP), rectal fluid (RF), and cervicovaginal fluid (CVF) at baseline; Days 3, 7, 14, and 28; and Weeks 12 and 24. Total and protein-unbound BIC concentrations at 24 hours postdose (C24h) were quantified in BP, SP, CVF and rectal tissue (RT) on Day 28 and Week 12 using a validated liquid chromatography-tandem mass spectrometry assay.ResultsThe study population comprised 15 males and 8 females. In SP, RF, and CVF, the baseline HIV-1 RNA was >40 copies/mL in 12/15, 13/15, and 4/8 individuals, respectively, with medians of 3.54 (2.41–3.79), 4.19 (2.98–4.70), and 2.56 (1.61–3.56) log10 copies/mL, respectively. The initial decay slope was significantly lower in SP than in RF and BP. The time to undetectable HIV-1 RNA was significantly shorter in SP and RF than in BP. All women achieved undetectable HIV-1 RNA in CVF at Day 14. The median total BIC concentrations in SP, RT, and CVF were 65.5 (20.1–923) ng/mL, 74.1 (6.0–478.5) ng/g, and 61.6 (14.4–1760.2) ng/mL, respectively, representing 2.7%, 2.6%, and 2.8% of the BP concentration, respectively, while the protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.ConclusionsBIC/FTC/TAF led to rapid decay of HIV-1 RNA in genital and rectal fluids. Protein-unbound BIC concentrations in SP, RT, and CVF highly exceeded the half-maximal effective concentration (EC50) value (1.1 ng/mL).Clinical Trials RegistrationEudraCT 2018-002310-12.
تدمد: 1537-6591
1058-4838
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a498cabbd8b10ffa3e3e6eb31d452fa
https://doi.org/10.1093/cid/ciaa1416
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....4a498cabbd8b10ffa3e3e6eb31d452fa
قاعدة البيانات: OpenAIRE